论文部分内容阅读
目的：探讨氟哌啶醇联合齐拉西酮注射液治疗精神分裂症患者急性激越症状的疗效和安全性。方法将94例伴急性激越症状的精神分裂症患者按入组顺序随机分为两组,均肌内注射氟哌啶醇注射液治疗,联合组联合肌内注射齐拉西酮注射液治疗,观察72 h。于治疗前后采用阳性与阴性症状量表及临床疗效总评量表病情严重程度分量表评定病情严重程度,阳性与阴性症状量表兴奋因子分评定兴奋激越症状改善状况,副反应量表评定不良反应。结果治疗72 h 后两组阳性与阴性症状量表及临床疗效总评量表病情严重程度分量表评分均较治疗前显著下降(P <0.01),联合组较对照组下降更显著(P <0.05)；治疗2 h 起联合组阳性与阴性症状量表兴奋因子评分较治疗前显著下降(P <0.05),治疗6 h 起两组兴奋因子分均较治疗前呈持续性下降(P 0.05)。治疗期间两组不良反应均较为轻微,联合组不良反应发生率显著低于对照组(χ2=4.61,P<0.05)。结论氟哌啶醇联合甲磺酸齐拉西酮注射液治疗精神分裂症患者伴急性激越症状较单用氟哌啶醇起效更快,疗效更显著,安全性更高,更有利于患者的后续治疗。“,”Objective To explore the efficacy and safety of haloperidol combined with injectable ziprasi-done in agitated symptoms of schizophrenia.Methods Ninety-four schizophrenics with acute agitated symptoms were randomly divided into two groups according to enrolment order,both groups were treated with injectable haloperidol,and combination group was plus injectable ziprasidone for 72 hours.Severities of patient’s condition were assessed with the Positive and Negative Syndrome Scale (PANSS)and Clinical Global Impression-severity of illness (CGI-SI)before and after treatment,improvement states of excited and agitated symptoms with excitation factor score of the PANSS,and adverse reactions with the Treat-ment Emergent Symptom Scale (TESS).Results After 72 hour treatment the PANSS and CGI-SI scores of both groups lowered more significantly compared with pretreatment (P <0.01),so did those in combi-nation than in control group (P <0.05 );since the 2 nd hour of treatment excitation factor score lowered more significantly compared with pretreatment in combination group (P < 0.05 ),since the 6 th those of both groups did continuously (P 0.05).During treatment adverse reactions of both groups were mild and the incidence of adverse reactions was significantly lower in combination than in con-trol group (χ2 = 4.61,P < 0.05 ).Conclusion Haloperidol combined with injectable ziprasidone takes effect more rapidly compared with single Haloperidol in acute agitated symptoms of schizophrenia,has an evident effect and higher safety,and is more beneficial to patients’follw-uptreatment.